Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma
Conditions
Interventions
Dabrafenib (DRB436) :oral, twice daily
Trametinib (TMT212) : oral, once daily
Sponsors
Yamauchi Kyosuke
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All Subjects: - Written informed consent, according to local guidelines, signed by the subjects and/or by the parents or legal guardian prior to any study related screening procedures are performed. - Participation in a Novartis sponsored study such as CTMT212X2101, CDRB436G2201, CDRB436A2102, regardless of current age. - Parent study (or cohort of parent study) is planned to be closed. - Subject has demonstrated compliance, as assessed by the investigator, within the parent study protocol requirement(s). - Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures. For Subjects Entering the Treatment Period: - Subject is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis Sponsored Drug Development study. Note that subjects who were on the chemotherapy arm of the CDRB436G2201 study are eligible for treatment period of this study only after crossing over into the experimental treatment arm of the CDRB436G2201 study - In the opinion of the investigator is likely to benefit from continued treatment.
Exclusion criteria
Exclusion criteria: All Subjects: - Subject has participated in a combination trial where dabrafenib and/or trametinib was dispensed in combination with another study medication. For Subjects Entering the Treatment Period: - Subject has permanently discontinued from study treatment in the parent protocol due to any reason. - Treatment with dabrafenib and/or trametinib for the subject's indication is approved for marketing and the appropriate dosage form is commercially available and reimbursed in the local country - Subject currently has unresolved drug related severe toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study. If the subject should meet criteria to resume treatment on the parent protocol then they may be eligible for treatment in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with Adverse Events and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to approximately 7 years ] To assess the long-term safety of treatment with dabrafenib, trametinib or the combination. | — |
Countries
Belgium, Canada, Czechia, Denmark, France, Germany, Japan, Netherlands, Russian Federation, Spain, United Kingdom, United States
Contacts
Public ContactKyosuke Yamauchi
Novartis Pharma. K.K.
Outcome results
None listed